荷载JQ1 /紫杉醇 PLGA纳米粒的制备

doi:10.3976/j.issn.1002-4026.2022.02.004

山东科学 ›› 2022, Vol. 35 ›› Issue (2): 29-35.doi: 10.3976/j.issn.1002-4026.2022.02.004

荷载JQ1 /紫杉醇 PLGA纳米粒的制备

刘骞¹,王沐芳¹,侯哲¹,王韶鸿¹,王慎兴¹,王鹏¹,刘芷萱¹,赵静^2,^*(),郝吉福^1,^*()

1.山东第一医科大学(山东省医学科学院) 药学院,山东泰安 271016
2.山东省泰山疗养院(山东省泰山医院),山东泰安 271016

收稿日期:2021-05-14 出版日期:2022-04-20 发布日期:2022-04-07
通信作者: 赵静,郝吉福 E-mail:yz.xyd@163.com;haojifu@163.com
作者简介:刘骞(1999—),女,研究方向为药学。
基金资助:
2020年山东省大学生创新创业训练计划项目(S202010439065)

Preparation of JQ1/paclitaxel-loaded PLGA nanoparticles

LIU Qian¹,WANG Mu-fang¹,HOU Zhe¹,WANG Shao-hong¹,WANG Shen-xing¹,WANG Peng¹,LIU Zhi-xuan¹,ZHAO Jing^2,^*(),HAO Ji-fu^1,^*()

1. College of Pharmaceutical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian 271016, China
2. Taishan Sanatorium of Shandong Province (Shandong Taishan Hospital), Taian 271016, China

Received:2021-05-14 Online:2022-04-20 Published:2022-04-07
Contact: Jing ZHAO,Ji-fu HAO E-mail:yz.xyd@163.com;haojifu@163.com

摘要/Abstract

摘要：

研究荷载JQ1/紫杉醇PLGA纳米粒的制备,并考察其对黑色素瘤细胞表面PD-L1表达情况的影响。采用乳化溶剂蒸发法制备荷载JQ1/紫杉醇的PLGA纳米粒,并对所制备的纳米粒进行粒径、形貌等理化性质表征;尾静脉注射荷载JQ-1/紫杉醇PLGA纳米粒后,考察大鼠体内的药动学参数;以B16黑色素瘤细胞为模型,应用流式细胞术分析PLGA纳米粒对B16细胞表面PD-L1表达情况的影响。结果表明,所制备的PLGA纳米粒平均粒径为210 nm,其外观呈光滑圆球状。大鼠体内单次静脉注射PLGA纳米粒后,呈二室模型分布,紫杉醇与JQ1主要的药动学参数如下:分布相半衰期为0.142 8、0.169 9 h,消除相半衰期为5.27、2.37 h,血药浓度曲线下面积为8.155、3.793 (μg·h)/mL,清除率为122.612、131.795 mL/(h·kg),表观分布体积为766.07、396.25 mL/kg。流式分析结果表明经PLGA纳米粒组处理后,可降低B16黑色素瘤细胞表面PD-L1的表达。表明所制备的PLGA纳米粒可作为紫杉醇与JQ1两种药物共递送的传输载体,有望提高免疫治疗肿瘤的效果。

关键词: 紫杉醇, JQ1, PLGA纳米粒, 黑色素瘤

Abstract:

This study aimed to prepare JQ1/paclitaxel (PTX)-loaded poly(lactic-co-gly-colic acid) (PLGA) nanoparticles and evaluate their effect on the expression of PD-L1 on melanoma cells. The JQ1/PTX-loaded PLGA nanoparticles were prepared using the emulsion solvent evaporation method, and their physicochemical properties, such as particle size and morphology were determined. The pharmacokinetic parameters of the JQ1/PTX-loaded PLGA nanoparticles were investigated in rats after administering the rats with a tail vein injection of the nanoparticles. The effect of the nanoparticles on the expression of PD-L1 on B16 melanoma cells was analyzed using flow cytometry. The results showed that the mean particle size of the prepared nanoparticles was about 210 nm and that they appeared smooth and spherical in shape. The main pharmacokinetic parameters of PTX and JQ1 determined using a two-compartment model after administering a single intravenous injection of the nanoparticles to the rats were as follows: the half-life of the distribution phase was 0.142 8 h and 0.169 9 h; half-life of the elimination phase was 5.27 and 2.37 h; area under the curve was 8.155 and 3.793(μg·h)/mL; clearance was 122.612 and 131.795 mL/(h·kg); and apparent volume of distribution was 766.07 and 396.25 mL/kg, respectively. Flow cytometry showed that the nanoparticles could reduce the expression of PD-L1 on B16 melanoma cells. Thus, the prepared PLGA nanoparticles can be used as carriers for the co-delivery of PTX and JQ1, which is expected to improve the effect of immunotherapy on tumors.

Key words: paclitaxel, JQ1, PLGA nanoparticles, melanoma

中图分类号:

R944.9

刘骞,王沐芳,侯哲,王韶鸿,王慎兴,王鹏,刘芷萱,赵静,郝吉福. 荷载JQ1 /紫杉醇 PLGA纳米粒的制备[J]. 山东科学, 2022, 35(2): 29-35.

LIU Qian,WANG Mu-fang,HOU Zhe,WANG Shao-hong,WANG Shen-xing,WANG Peng,LIU Zhi-xuan,ZHAO Jing,HAO Ji-fu. Preparation of JQ1/paclitaxel-loaded PLGA nanoparticles[J]. Shandong Science, 2022, 35(2): 29-35.

图/表 4

参考文献 14

[1]	RILEY R S, JUNE C H, LANGER R, et al. Delivery technologies for cancer immunotherapy[J]. Nature Reviews Drug Discovery, 2019, 18(3): 175-196. DOI: 10.1038/s41573-018-0006-z. doi: 10.1038/s41573-018-0006-z
[2]	MUSETTI S, HUANG L. Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy[J]. ACS Nano, 2018, 12(12): 11740-11755. DOI: 10.1021/acsnano.8b05893. doi: 10.1021/acsnano.8b05893
[3]	WANG H R, TANG Y S, FANG Y F, et al. Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of shikonin/JQ1[J]. Nano Letters, 2019, 19(5): 2935-2944. DOI: 10.1021/acs.nanolett.9b00021. doi: 10.1021/acs.nanolett.9b00021
[4]	QI J, JIN F Y, XU X L, et al. Combination cancer immunotherapy of nanoparticle-based immunogenic cell death inducers and immune checkpoint inhibitors[J]. International Journal of Nanomedicine, 2021, 16: 1435-1456. DOI: 10.2147/IJN.S285999. doi: 10.2147/IJN.S285999
[5]	JIN Q T, LIU Z, CHEN Q. Controlled release of immunotherapeutics for enhanced cancer immunotherapy after local delivery[J]. Journal of Controlled Release, 2021, 329: 882-893. DOI: 10.1016/j.jconrel.2020.10.019. doi: 10.1016/j.jconrel.2020.10.019
[6]	ZHONG Y, SU T, SHI Q X, et al. Co-administration of iRGD enhances tumor-targeted delivery and anti-tumor effects of paclitaxel-loaded PLGA nanoparticles for colorectal cancer treatment[J]. International Journal of Nanomedicine, 2019, 14: 8543-8560. DOI: 10.2147/IJN.S219820. doi: 10.2147/IJN.S219820
[7]	ZHANG M, DAI Z, THEIVENDRAN S, et al. Nanotechnology enabled reactive species regulation in biosystems for boosting cancer immunotherapy[J]. Nano Today, 2021, 36: 101035. DOI: 10.1016/j.nantod.2020.101035. doi: 10.1016/j.nantod.2020.101035
[8]	CHOI J S, CAO J F, NAEEM M, et al. Size-controlled biodegradable nanoparticles: preparation and size-dependent cellular uptake and tumor cell growth inhibition[J]. Colloids and Surfaces B: Biointerfaces, 2014, 122: 545-551. DOI: 10.1016/j.colsurfb.2014.07.030. doi: 10.1016/j.colsurfb.2014.07.030
[9]	HARADA A, TSUTSUKI H, ZHANG T L, et al. Preparation of biodegradable PLGA-nanoparticles used for pH-sensitive intracellular delivery of an anti-inflammatory bacterial toxin to macrophages[J]. Chemical & Pharmaceutical Bulletin, 2020, 68(4): 363-368. DOI: 10.1248/cpb.c19-00917. doi: 10.1248/cpb.c19-00917
[10]	ACHARYA S, SAHOO S K. PLGA nanoparticles containing various anticancer agents andtumour delivery by EPR effect[J]. Advanced Drug Delivery Reviews, 2011, 63(3): 170-183. DOI: 10.1016/j.addr.2010.10.008. doi: 10.1016/j.addr.2010.10.008
[11]	庄倩楠, 韩特, 吴超男, 等. 冬凌草甲素纳米粒的制备及其在大鼠体内的药动学研究[J]. 药学服务与研究, 2019, 19(1): 16-18 DOI: 10.5428/pcar20190105. doi: 10.5428/pcar20190105
[12]	KALYANE D, RAVAL N, MAHESHWARI R, et al. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer[J]. Materials Science& Engineering C, Materials for Biological Applications, 2019, 98: 1252-1276. DOI: 10.1016/j.msec.2019.01.066. doi: 10.1016/j.msec.2019.01.066
[13]	HASSAN R, TAMMAM S N, SAFY S E, et al. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis[J]. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 134: 96-106. DOI: 10.1016/j.ejpb.2018.11.018. doi: 10.1016/j.ejpb.2018.11.018
[14]	MARTIN J D, CABRAL H, STYLIANOPOULOS T, et al. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges[J]. Nature Reviews Clinical Oncology, 2020, 17(4): 251-266. DOI: 10.1038/s41571-019-0308-z. doi: 10.1038/s41571-019-0308-z

荷载JQ1 /紫杉醇 PLGA纳米粒的制备

Preparation of JQ1/paclitaxel-loaded PLGA nanoparticles

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 14

相关文章 0

Metrics

本文评价

推荐阅读 0